Table 2.
First line therapy for patients with BRAFV600E mutated colorectal cancer.
| Regimen | Partial response | Stable disease | Progression disease | mPFS (months) |
|---|---|---|---|---|
| Bevacizumab + FOLFOXIRI (N = 11) | 6 | 3 | 2 | 8.8 |
| Bevacizumab + FOLFOX/FOLFIRI/XELOX (N = 9) | 2 | 5 | 2 | 9.1 |
| FOLFOXIRI/FOLFOX/FOLFIRI/XELOX (N = 19) | 4 | 8 | 7 | 4.6 |
| Cetuximab + FOLFOX/FOLFIRI (N = 2) | 0 | 2 | 0 | 4.3 |